// App-Quantinova.ai

: Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders

Researchers

Presenter

  • Mattia Algeri

Principal Investigators

  • Pietro Merli

  • Waseem Qasim

  • Mary Slatter

  • Melissa Kuhn

  • Franco Locatelli

Medical Centers

  • Stem Cell Transplant - Cell and Gene Therapy Unit, Ospedale Bambino Gesù, Rome, Italy

  • Department of Pediatric Hematology and Oncology, Cell and Gene Therapy,IRCCS Bambino Gesù Children's Hospital,Roma,Italy

  • Bone Marrow Transplantation Department, Institute of Child Health / Molecular and Cellular Immunology Unit, University College London, LONDON, United Kingdom

  • Great North Children's Hospital, Newcastle, United Kingdom

  • Bellicum Pharmaceutical, Inc., Brisbane, CA

  • Department of Pediatric Hematology and Oncology , IRCCS Ospedale Bambino Gesu, Rome , Italy

Locations

  • Italy

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • Rimiducid

  • BPX-501

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT02065869

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved